```
=> d 14
L4 HAS NO ANSWERS
L4                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s 14
SAMPLE SEARCH INITIATED 14:45:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L5            0 SEA SSS SAM L4

=>
Uploading C:\Documents and Settings\EBernhardt\My
Documents\Stnexp\Queries\10572670-2.str
```





chain nodes :
17 18 19 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 20 21 22 23 24 25
chain bonds :
1-14 8-17 11-27 17-21 17-18 17-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16 20-21 20-25 21-22 22-23 23-24 24-25
exact/norm bonds :
1-14 8-17 11-12 11-16 12-13 13-14 14-15 15-16 17-21 17-18 17-19
exact bonds :
11-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 20-21 20-25 21-22 22-23
23-24 24-25
isolated ring systems :
containing 1 : 20 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 27:CLASS

L6 STRUCTURE UPLOADED

=> s l6
SAMPLE SEARCH INITIATED 14:47:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 22 TO ITERATE

100.0% PROCESSED 22 ITERATIONS 2 ANSWERS

```
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:            159 TO      721
PROJECTED ANSWERS:                 2 TO      124

L7            2 SEA SSS SAM L6

=> d 16
L6 HAS NO ANSWERS
L6              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s 16 sss full
FULL SEARCH INITIATED 14:48:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      446 TO ITERATE

100.0% PROCESSED      446 ITERATIONS                                45 ANSWERS
SEARCH TIME: 00.00.01

L8           45 SEA SSS FUL L6

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   180.20     361.41

FILE 'CAPLUS' ENTERED AT 14:48:11 ON 02 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 2 Feb 2008  VOL 148 ISS 6
FILE LAST UPDATED: 1 Feb 2008  (20080201/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 18
```

```
L9           5 L8

=> d l9 1-5 bib abs hitstr

L9   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2007:410374  CAPLUS
DN   146:402011
TI   Process for preparation of 8-amino-3-phenylsulfonylquinolines from
     8-fluoro-3-phenylsulfonylquinoline and amines in the presence of base and
     solvent.
IN   Wade, Charles Edward
PA   Glaxo Group Limited, UK
SO   PCT Int. Appl., 26pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------          ----   --------    -------------------    --------
PI   WO 2007039238       A1     20070412    WO 2006-EP9460         20060926
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
             KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
             MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
             RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRAI GB 2005-19758        A     20050928
OS   CASREACT 146:402011; MARPAT 146:402011
GI
```



I

```
AB   Title compds. [I; R1, R2 = H, alkyl; NR1R2 = (substituted) 4-7 membered
     heterocyclyl], were prepared by reaction of 8-fluoro-3-
     phenylsulfonylquinoline with R1R2NH (variables as above) in the presence
     of base and solvent.  Thus, 8-fluoro-3-phenylsulfonylquinoline (preparation
     given), piperazine, and K2CO3 were heated together in n-propanol at
     100° for 23 h to give 86% 3-phenylsulfonyl-8-piperazin-1-
     ylquinoline.  Polymorphic forms II and III of the latter were prepared via
     recrystn.
IT   607742-69-8P, 3-Phenylsulfonyl-8-piperazin-1-ylquinoline
```

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of aminophenylsulfonylquinolines from fluorophenylsulfonylquinolines and amines in the presence of base and solvent)

RN 607742-69-8 CAPLUS

CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:493996 CAPLUS

DN 145:8187

TI Preparation of isotopomeric piperazine-containing ligands labeling and diagnostic imaging of 5-HT6 receptors

IN Gee, Antony David; Martarello, Laurent; Johnson, Christopher Norbert; Witty, David R.

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006053785	A1	20060526	WO 2005-EP12463	20051117
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	CA 2588381	A1	20060526	CA 2005-2588381	20051117
	EP 1824830	A1	20070829	EP 2005-807786	20051117
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR
PRAI GB 2004-25548 A 20041119
WO 2005-EP12463 W 20051117
OS CASREACT 145:8187; MARPAT 145:8187
GI



I

AB Piperazine-containing ligands [I; R1 = 3H, 11C, 13N, 15O, 76Br, 18 F, 123I, 125I, 131I, 75Br, 76Br, 77Br, 82Br, 211At; R2 = F; or R1 = C1-4 (fluoro)alkyl and R2 = 3H, 11C, 13N, 15O, 76Br, 18 F, 123I, 125I, 131I, 75Br, 76Br, 77Br, 82Br, 211At; e.g., (11C-N-methyl)-3-[(3-fluorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)quinoline; 5-HT6 receptor pKi 9.82], which are useful for the labeling and diagnostic imaging of 5-HT6 receptors functionality and the treatment of CNS related disorders, are prepared
IT 607743-50-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(in the preparation of isotopomeric piperazine-containing ligands labeling and
diagnostic imaging of 5-HT6 receptors)
RN 607743-50-0 CAPLUS
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:395276 CAPLUS
DN 142:430310
TI Process for the preparation of a crystal polymorphic form of 3-phenylsulfonyl-8-piperazin-1-ylquinoline
IN Gladwin, Asa Elisabeth
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040124	A1	20050506	WO 2004-EP10843	20040923
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004283805	A1	20050506	AU 2004-283805	20040923
	CA 2540022	A1	20050506	CA 2004-2540022	20040923
	EP 1667975	A1	20060614	EP 2004-765655	20040923
	EP 1667975	B1	20071128		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1856471	A	20061101	CN 2004-80027527	20040923
	BR 2004014678	A	20061128	BR 2004-14678	20040923
	JP 2007506702	T	20070322	JP 2006-527373	20040923
	IN 2006DN00970	A	20070817	IN 2006-DN970	20060224
	US 2007032504	A1	20070208	US 2006-572670	20060320
	MX 2006PA03375	A	20060608	MX 2006-PA3375	20060324
	KR 2007020372	A	20070221	KR 2006-705895	20060324
	NO 2006001791	A	20060424	NO 2006-1791	20060424
PRAI	GB 2003-22629	A	20030926		
	WO 2004-EP10843	W	20040923		

OS CASREACT 142:430310
AB Polymorphic crystalline forms of 3-phenylsulfonyl-8-piperazin-1-ylquinoline are synthesized, characetrized, and claimed in the treatment of CNS (e.g., schizophrenia) and other disorders.
IT 607742-69-8P, 3-Phenylsulfonyl-8-piperazin-1-ylquinoline
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for the preparation of a crystal polymorphic form of 3-phenylsulfonyl-8-piperazin-1-ylquinoline)
RN 607742-69-8 CAPLUS
CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:260030 CAPLUS
DN 142:336394
TI Preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders
IN Johnson, Christopher Norbert; Witty, David R.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026125	A1	20050324	WO 2004-EP10129	20040909
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1663980	A1	20060607	EP 2004-765057	20040909
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007505075	T	20070308	JP 2006-525773	20040909
	US 2006287334	A1	20061221	US 2006-571405	20060310
PRAI	GB 2003-21473	A	20030912		
	WO 2004-EP10129	W	20040909		

OS CASREACT 142:336394; MARPAT 142:336394
GI



I



II

AB Title compds. I [R1 = (un)substituted alkyl, alkylcycloalkyl, alkoxyalkyl, alkyl(hetero)aryl, alkylheterocyclyl; R2 = H or alkyl; m = 1-4; when m > 1, two R2 groups may be linked to form a CH2, (CH2)2 or (CH2)3 group; R3-R5 = independently H, halo, CN, CF3, OCF3, alkyl, alkoxy, alkanoyl, CONH2 and derivs.; n = 1 - 3; p = 1-2; and their pharmaceutically acceptable salts] were prepared as 5HT6 receptor antagonists in treatment of CNS disorders. Thus, condensation of 3-phenylsulfonyl-8-(piperazin-1-yl)quinoline (preparation given) with 4-fluorobenzaldehyde gave II. I were tested and showed good affinity for the 5-HT6 receptor, having pKi values ≥ 7.0 at human cloned 5-HT6 receptors.

IT 607742-55-2P, 3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline hydrochloride 607742-69-8P, 3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders)

RN 607742-55-2 CAPLUS

CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-69-8 CAPLUS
CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:777764 CAPLUS
DN 139:292163
TI Preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders
IN Ahmed, Mahmood; Johnson, Christopher Norbert; Jones, Martin C.; MacDonald, Gregor James; Moss, Stephen Frederick; Thompson, Mervyn; Wade, Charles Edward; Witty, David
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080580	A2	20031002	WO 2003-EP3197	20030325
	WO 2003080580	A3	20040205		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2479786	A1	20031002	CA 2003-2479786	20030325
	AU 2003219103	A1	20031008	AU 2003-219103	20030325
	EP 1497266	A2	20050119	EP 2003-714889	20030325
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008696	A	20050125	BR 2003-8696	20030325
	CN 1656075	A	20050817	CN 2003-811644	20030325

	JP 2005531518	T	20051020	JP 2003-578335	20030325
	TW 268928	B	20061221	TW 2003-92106558	20030325
	RU 2309154	C2	20071027	RU 2004-131641	20030325
	ZA 2004007320	A	20051004	ZA 2004-7320	20040912
	IN 2004DN02703	A	20070302	IN 2004-DN2703	20040914
	MX 2004PA09318	A	20050125	MX 2004-PA9318	20040924
	US 2005124628	A1	20050609	US 2004-509078	20040927
	NO 2004004588	A	20041025	NO 2004-4588	20041025
PRAI	GB 2002-7289	A	20020327		
	GB 2002-25678	A	20021104		
	WO 2003-EP3197	W	20030325		

OS MARPAT 139:292163

GI



I

AB Title compds. I [R1, R2 = H, alkyl; R1R2, R22 = (CH2)2-4; R3-R5 = H, halogen, CN, CF3, OCF3, alkyl, alkoxy, alkanoyl, (un)substituted CONH2; A = (un)substituted aryl; m = 1-4; n = 1-3, p = 1, 2] were prepared for use as HT6 receptor antagonists in treatment of CNS disorders. Thus, 8-iodo-3-phenylsulfonylquinoline was prepared from 8-nitroquinoline and was treated with 1-tert.-butoxycarbonylpiperazine, followed by deblocking, to give 3-phenylsulfonyl-8-piperazinoquinoline.

IT 607742-55-2P 607742-69-8P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders)

RN 607742-55-2 CAPLUS

CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-69-8 CAPLUS
CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



IT 607742-56-3P 607742-57-4P 607742-58-5P
607742-59-6P 607742-60-9P 607742-61-0P
607742-62-1P 607742-63-2P 607742-64-3P
607742-65-4P 607742-66-5P 607742-68-7P
607742-71-2P 607742-72-3P 607742-73-4P
607742-74-5P 607742-75-6P 607742-85-8P
607742-86-9P 607742-87-0P 607742-88-1P
607742-89-2P 607742-90-5P 607742-92-7P
607742-93-8P 607742-94-9P 607742-95-0P
607742-96-1P 607742-97-2P 607743-04-4P
607743-46-4P 607743-47-5P 607743-48-6P
607743-49-7P 607743-50-0P 607743-51-1P
607743-52-2P 607743-53-3P 607743-54-4P
607743-55-5P 607743-56-6P 607743-58-8P
607743-60-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders)
RN 607742-56-3 CAPLUS

CN Quinoline, 3-[(2-chlorophenyl)sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-57-4 CAPLUS
CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-58-5 CAPLUS
CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-59-6 CAPLUS
CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-60-9 CAPLUS
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-61-0 CAPLUS
CN Quinoline, 3-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-62-1 CAPLUS
CN Quinoline, 8-(1-piperazinyl)-3-[[3-(trifluoromethyl)phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-63-2 CAPLUS
CN Quinoline, 7-chloro-3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-64-3 CAPLUS
CN Quinoline, 6-methyl-3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-65-4 CAPLUS
CN Quinoline, 8-[(3R)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 607742-66-5 CAPLUS
CN Quinoline, 8-[(3S)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 607742-68-7 CAPLUS
CN Quinoline, 8-[(2S)-2-methyl-1-piperazinyl]-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 607742-71-2 CAPLUS
CN Quinoline, 3-[(2-methylphenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607742-72-3 CAPLUS
CN Quinoline, 3-[(2-methoxyphenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607742-73-4 CAPLUS
CN Quinoline, 3-[(4-methylphenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607742-74-5 CAPLUS
CN Quinoline, 3-[(4-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607742-75-6 CAPLUS
CN Quinoline, 8-(1-piperazinyl)-3-[[2-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 607742-85-8 CAPLUS
CN Quinoline, 3-[(2-methylphenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607742-86-9 CAPLUS
CN Quinoline, 3-[(2-methoxyphenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607742-87-0 CAPLUS
CN Quinoline, 3-[(4-methylphenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 607742-88-1 CAPLUS
CN Quinoline, 3-[(4-fluorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 607742-89-2 CAPLUS
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 607742-90-5 CAPLUS
CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 607742-92-7 CAPLUS
CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 607742-93-8 CAPLUS
CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 607742-94-9 CAPLUS
CN Quinoline, 8-[(3S)-3-methyl-1-piperazinyl]-3-[[2-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607742-95-0 CAPLUS
CN Quinoline, 8-[(2R)-2-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607742-96-1 CAPLUS
CN Quinoline, 8-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-3-(phenylsulfonyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 607742-97-2 CAPLUS
CN Quinoline, 8-(3,3-dimethyl-1-piperazinyl)-3-(phenylsulfonyl)- (CA INDEX NAME)



RN 607743-04-4 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[3-(phenylsulfonyl)-8-quinolinyl]-, monohydrochloride, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 607743-46-4 CAPLUS
CN Quinoline, 3-[(2-chlorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-47-5 CAPLUS
CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-48-6 CAPLUS
CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-49-7 CAPLUS
CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-50-0 CAPLUS
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-51-1 CAPLUS
CN Quinoline, 3-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-52-2 CAPLUS
CN Quinoline, 8-(1-piperazinyl)-3-[[3-(trifluoromethyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 607743-53-3 CAPLUS
CN Quinoline, 7-chloro-3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-54-4 CAPLUS
CN Quinoline, 6-methyl-3-(phenylsulfonyl)-8-(1-piperazinyl)- (CA INDEX NAME)



RN 607743-55-5 CAPLUS
CN Quinoline, 8-[(3R)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607743-56-6 CAPLUS
CN Quinoline, 8-[(3S)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607743-58-8 CAPLUS
CN Quinoline, 8-[(2S)-2-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 607743-60-2 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[3-(phenylsulfonyl)-8-quinolinyl]-, (1S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



```
=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    27.73     389.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -4.00      -4.00

FILE 'CAOLD' ENTERED AT 14:48:43 ON 02 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file supports REGlstRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> s l8
L10             0 L8

=> file chemcats
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.46     389.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

CA SUBSCRIBER PRICE 0.00 -4.00

FILE 'CHEMCATS' ENTERED AT 14:48:52 ON 02 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE LAST UPDATED 26 JANUARY 2008 (20080126/UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow prompt. For the list of suppliers currently in the file, enter HELP SPA, HELP SPB, HELP SPC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPQZ. For the list of current catalogs, enter HELP CTA, HELP CTB, HELP CTC, HELP CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis. Please consult the suppliers for current information regarding pricing, regional availability, available quantities, purities, etc. THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not liable for any loss of profit, goodwill or any other damages arising out of the use of this database.

CHEMCATS now contains more than 20 million records. See HELP CONTENT and NEWS FILE for details.

=> s l8
L11 0 L8

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.94	390.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.00

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:49:04 ON 02 FEB 2008